Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2023 08:30 ET | Source: Ambrx Biopharma Inc.

Ambrx to Present Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting

SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), announced the presentation of three posters featuring preclinical data at the upcoming 2023 American...
November 29, 2022 08:30 ET | Source: Ambrx Biopharma Inc.

Interim Data from Ambrx’s Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium

SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs)...
October 18, 2022 16:05 ET | Source: Ambrx Biopharma Inc.

Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update

- Company now focused on earlier stage engineered antibody drugs for cancer therapies, including new lead asset ARX517 – - Revised focus and projected cost-reductions expected to extend cash runway...
October 11, 2022 16:05 ET | Source: Ambrx Biopharma Inc.

Ambrx Biopharma to Host Corporate Update Conference Call

SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create...